Twenty years ago when Children's Cancer Association of Japan was born, the diagnosis of childhood leukemia amounted to a death sentence. Only 20% or so of children with leukemia survived more than 5 years. Since then, enormous improvements have been achieved regarding our understanding on the etiology, diagnosis, and the treatment of childhood leukemia. Now, 70% of children with leukemia survive and enter adult life. Even though the improved survival rate of children with leukemia represents a medical success story, we now face new problems. The first problem is the fact that we still lose 20-30% of patients with childhood leukemia. To address this problem, we need to understand the etiology, epidemiology, and biology of leukemia; to identify the patients at greater risk; and to develop adequate treatments. The second problem is the treatment itself. Even though efficacious, the modem treatment for leukemia is a grueling experience for children and their families. We should develop a total care system for families and children based on a deep understanding of their needs. The third problem is the aftereffects of the treatment and of cured leukemia. Extensive radiation and chemotherapy have an entirely different spectrum of long-term effects on children than on adults. These treatments in the early stage of life, when the mind and body are developing, create many physical and psychological problems. These are the present problems of childhood leukemia.

Primary lung tumors are now a global health problem. The incidence has risen dramatically during the last 5--6 decades, reflecting the popularity of cigarette smoking. In this, the fifth volume dealing with lung cancer in the series KappaCANCER TREATMENT AND RESEARCHkappa, many current research topics are covered by notable authorities, including chemoprevention, growth factors, multidrug resistance, new agents, and haematopoietic growth factors. Altogether, the 17 chapters from twelve countries highlight some of the rapid developments taking place in basic and clinical research of lung cancer. These chapters not only give up-to-date information, they will also stimulate further research into this man-made disease which was almost unheard of a century ago.

Introduction of new technologies and their applications to neuroblastoma diagnosis, treatment, and therapy assessment are explained. Role of molecular ghenetics in diagnosis and therapy for neuroblastoma patients is detailed. Molecular detection of minimal residual neuroblastoma is described. Magnetic resonance imaging and spectroscopy are detailed for diagnosing this solid, extracranial cancer. Targets for therapeutic intervention in neuroblastoma are identified, including targeting multidrug resistance in this cancer. Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. The effectiveness of chemotherapy with oral irinotecan and temozolomide is explained. The role of transcription factors (GATA) in neuroblastoma pregression is also included.

Capsaicin is a principal pungent ingredient of red chili peppers, first isolated in the early nineteenth century by Christian Friedrich Bucholz. Widely consumed as a spice in South Asia and Latin America, Capsaicin has been used to treat pain and inflammation associated with a variety of diseases, including rheumatoid arthritis, diabetic neuropathy, post-masectomy pain, cluster headaches, and herpes zoster. Although recent studies have evaluated capsaicin as a novel anti-cancer agent, and mechanisms of capsaicin in preventing cancer have been described sporadically, the literature lacks a comprehensive review of capsaicin as a chemo-preventive agent. Role of Capsaicin in Oxidative Stress and Cancer offers a thorough exploration of the preventive and therapeutic effects of capsaicin in cancer models such as melanoma, pancreatic cancer, colon cancer, gastric cancer, breast cancer, prostate cancer, skin cancer, lung cancer, multiple myeloma and glioma. The contributors, all internationally recognized researchers, identify various molecular and cellular targets of capsaicin, and show the critical role of mitochondria in capsaicin-mediated therapeutic effects. Readers will learn how capsaicin prevents or may treat cancer, how different cells respond to capsaicin, how environmental carcinogen-induced carcinogenesis can be prevented by capsaicin and the mechanism of oxidative stress caused by capsaicin. This book will benefit medical students, oncologists and cancer researchers everywhere.

An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.

Between 1990 and 1993, breast cancer activism became a significant political movement. The issue began to receive extensive media attention, and federal funding for breast cancer research jumped dramatically. Describing the origins of this surge in interest, Maureen Hogan Casamayou attributes it to the emergence of politically potent activism among breast cancer survivors and their supporters. Exploring the creation and development of the National Breast Cancer Coalition (NBCC), she shows how many of its key leaders were mobilized by their own traumatic experiences with the disease and its treatments.

Casamayou details the NBCC's meteoric rise and impressive lobbying efforts, explaining how -- in contrast to grassroots movements founded by dedicated individuals -- the coalition grew from the simultaneous efforts of a network of women who invested their time, energy, money, and professional skills in the fight for increased funding for breast cancer research. This multiple leadership -- or collective entrepreneurialism, says Casamayou -- was crucial to the NBCC's success framing the issue in the minds of the public and policymakers alike.

Cancer Informatics: Essential Technologies for Clinical Trials describes the National Cancer Institute¿s vision of a Cancer Informatics Infrastructure (CII). By exploiting the best that the Internet and information technology have to offer, the CII will facilitate clinical trials, for all who are involved, including the patient along with the myriad of health professionals involved in cancer trials. To bridge the chasm between discoveries and best clinical practices, the editors describe the CII and how it can function to expedite the clinical trial life cycle, facilitate faster and safer drug development, and make more appropriate treatment choices available to cancer patients. Presented in four comprehensive sections edited by leading experts, the book highlights: ¿ E-commerce ¿ Digital libraries ¿ Standards development ¿ Public health informatics ¿ Common data elements (CDEs) ¿ Clinical trials information systems ¿ Consumer education and support Cancer Informatics: Essential Technologies for Clinical Trials is an indispensable guide to clinical trials. Its contributors speak to oncologists and primary care physicians, as well as researchers, trial managers, administrators, informaticians, and consumers. Today, science is extending our knowledge of genes, proteins, and pathways, and pharmaceutical companies are developing more and more new therapies. In this rapidly changing world, the technologies that cancer informatics provides are essential to efforts to translate cancer research into cancer care, control, and, ultimately, prevention. John S. Silva, M.D., Center for Bioinformatics, National Cancer Institute Marion J. Ball, Ed.D., Vice President, Clinical Solutions, Healthlink, Inc.; Adjunct Professor, The Johns Hopkins University School of Nursing Christopher G. Chute, M.D., Dr.P.H., Professor of Medical Informatics, Head, Section of Medical Information Resources, Mayo Clinic Judith V. Douglas, M.A., M.H.S., formerly Associate, First Consulting Group Curtis P. Langlotz, M.D., Ph.D., Assistant Professor of Radiology, Epidemiology, and Computer and Information Science, University of Pennsylvannia Joyce. C. Niland, Ph.D., Chair, Division of Information Sciences, Director, Department of Biostatistics, City of Hope National Medical Center William L. Scherlis, Ph.D., Principal Research Scientist, School of Computer Science, Carnegie Mellon University

The fifth Annual Pezcoller Symposium entitled, Apoptosis, was held in Trento, Italy, June 9-1I, 1993 and was focused on the specific phenomena leading to Programmed Cell Death (PCD) or Apoptosis, and the mechanisms involved. With presentations at the cutting edge of progress and stimulating discussions, this Symposium addressed the genetics and molecular mechanisms determining PCD and the role of this suicidal process in cancer and the immune system. The functions of pS3, c myc and bel 2 in affecting apoptosis in different cell types and the role of ions and intracellular pH changes and that of intranuelear endonueleases are given particular emphasis as are the effects of anticancer agents, hormone imbalances and growth factors. The role of pS3, a tumor suppressor gene, in inducing PCD is discussed in detail as pertinent to hematological and non-hernatological tumors. The requirement of pS3 for the induction ofapoptosis by ionizing radiation or adenovirus oncoproteins is outlined. Decision points during the cell cyele affecting the cascade ofevents leading to PCD are discussed as is their role as "switches" under the control of c-myc and bel-2 proteins or the influence of cyele specific drugs. The concurrent requirement of multiple signals in determining apoptosis is emphasized. The examples of the role of PCD in the regulation of hematopoiesis, and in the generation of antigen-specific immune repertoire are illustrated.

This book discusses the mechanisms leading to immune-mediated tissue rejection following the hypothesis that independent of the disease process the final effector mechanism is shared by most (but not all) pathologies and it is relatively simple. The book covers evidence gathered to support the thesis by studies performed in humans during rejection or in experimental models and will focus particularly (but not exclusively) on the analysis of the rejected tissue rather than the systemic circulation. Several disease processes are discussed including example of chronic inflammatory process without resolution of the pathologic process and acute one with resolution of the pathologic process (clearance of pathogen, rejection of tumor) or unwanted tissue destruction (allograft rejection, autoimmunity).

More often than not, progress in medicine occurs incrementally. The report of an 'important' new observation is typically greeted by a mixture of excitement and skepticism. Yet the true value of the discovery may not be known for several years until it is confirmed (or refuted) by independently conducted studies. In some cases, controversy may continue to shroud a topic due to the discordant results generated by different research groups. Since the last Gynecologic Oncology volume in the Cancer Treatment and Research series, a number of new areas have emerged that shed new light on the pathogenesis, diagnosis, and treatment of gynecologic malignancies. In this volume of the Cancer Treatment and Research series, I have attempted to integrate articles that highlight some of these newest developments with chapters that provide an overview of selected areas of controversy. This volume is not meant to be an abbreviated text of gynecologic oncology but rather a collection of selected works that can provide the reader with a better perspective on the areas of change within the field. The application of molecular biology to cervical cancer has allowed us to understand more completely the roles of human papilloma viruses and cellular oncogenes in the development of cancer of the uterine cervix.

This volume explores pericytes' roles under distinct pathological conditions, ranging from tumors, ALS, Alzheimer's disease, Multiple Sclerosis, stroke, diabetes, atherosclerosis, muscular dystrophies and more. Together with its companion volumes Pericyte Biology in Different Organs and Pericyte Biology - Novel Concepts, Pericyte Biology in Disease presents a comprehensive update on the latest information and most novel functions attributed to pericytes. To those researchers newer to this area, it will be useful to have the background information on these cells' unique history. It will be invaluable for both advanced cell biology students as well as researchers in cell biology, stem cell biology and clinicians involved with these specific diseases.

The Vascular Endothelium: A Holistic Approach for Oncology provides novel and integrated knowledge on the endothelial cells as a crucial component involved in the growth of different organs in both physiological and pathological conditions. By covering diverse aspects of anatomy, embryology, molecular biology and pathology, it details the important role of the endothelium for the pathogenesis of cancer and how this knowledge can improve the outcome of cancer research. The content is split in six parts: appearance and evolution of the endothelial cell, which discusses for instance comparative anatomy of the endothelium in relation to the vascular system; endothelial cell in embryology and organogenesis, covering the interaction between endothelial and hematopoietic cells; the lymphatic system, which brings information on lymphatic endothelial cell markers and molecular regulation of lymphangiogenesis; the anatomy of the endothelium in adults, showing the differences in the mature endothelial cells through the body; the physiology of the endothelial cells, with organ specific physiological activity of the endothelium; and the endothelial cells in cancer, discussing the use of endothelium as target for treatment and current therapeutic approaches. This book is a valuable resource for cancer researchers, oncologists and other members of biomedical field who are interested to learn more about the complexity of vascular endothelium and its impact on cancer and other related diseases.

This volume evaluates the carcinogenic risk to humans posed by infection with human papillomaviruses (HPVs). To date, more than 70 HPV types have been identified, of which over 15 have been reported in cervical cancer biopsies. Worldwide, cervical cancer is the second most common cancer in women. This book also considers the possible involvement of HPV infection in cancers at other sites of the human body.

Our recent understanding of the cellular and molecular defects and the regulation of the apoptotic signalling pathways has resulted in rationally designed anticancer strategies and the development of novel agents that regulates apoptosis. A comprehensive review of all apoptotic-related anticancer therapies is not the purpose of this book. However, in the volume of this book with 11 chapters, we have described a number of novel apoptotic regulators that have shown promising value and also great feasibility for cancer treatment. These novel agents either occur naturally or are chemically synthesized. While we are excited about the discovery and development of these novel apoptotic regulators as potential anticancer agents, a degree of caution should be always borne in mind when interpreting the success of preclinical pro-apoptotic candidates since potential problems inevitably lie ahead. These problems usually include target specificity, unanticipated toxicity, compound stability, formulation issues, pharmacokinetic and pharmacodynamic profiles. Nevertheless, we believe that this collection of 11 chapters by established leaders in the area of apoptosis will be of great interest to not only academics working in the field of cancer research and apoptosis but also pharmaceutical and pharmacological industries that . We are looking forward to the further development to push these potential agents toward clinical stage.

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology text books are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good in-depth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes that aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, and easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion: first, by dividing the oncology literature into specific subdivisions such as lung cancer, geni tourinary cancer, pediatric oncology, etc.; and second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

This volume is unique in reporting on strategies for the application of molecular targeted imaging agents such as antibodies, peptides, receptors and contrast agents in the biologic grading of tumors, differential diagnosis of tumors, prediction of therapeutic response and monitoring tumor response to treatment. It also includes updated information on the imaging of tumor angiogenesis, hypoxia, apoptosis and gene delivery as well as expression in the understanding and utility of tumor molecular biology for better cancer management.

Over the past decade, techniques have been developed and implemented to observe metabolism noninvasively in localized regions of intact, living experimental animals and humans through the use of magnetic resonance spectroscopy (MRS). At the same time, magnetic resonance imaging (MRI) techniques developed in the 1970s and refined in this decade have been increasingly applied as a powerful clinical tool to probe human anatomy. Because of the unusual metabolic and physiologic characteristics of malignant tissues, oncology has been one of the primary focuses of the application of both MRS and MRI. Although considerable progress has been made in oncologic applications of magnetic resonance (MR), further research is needed to realize the full potential of MR in this area. Consequently, the 21st Annual Detroit Cancer Symposium entitled "Magnetic Resonance in Experimental and Clin ical Oncology" was organized to provide a forum for researchers in the field to report the state of the art of MRS and MRI in oncol ogy, to discuss future goals for MRS and MRI in oncology, and to define the research needed to meet those goals. The major emphasis of the symposium was on MRS due to both the recent widespread availability of clinical MRS instrumentation and the extensive amount of animal MRS research performed over the past half decade."

In the recent years, a significant amount of research has emerged connecting the link between alcohol and cancer. The field has rapidly advanced, especially since the complex connection between alcohol and cancer has several unique sub areas that are being investigated. This proceedings volume will contain chapters based upon the presentation of the 2nd International Conference on Alcohol and Cancer in Colorado, 2013. The various topics explore the affects of alcohol on: liver and breast cancer; cell signaling and cancer; stem cells; biomarkers and metabolomics; aerodigestive cancers; cancer and the immune system and more.

This book illustrates the importance of the Natural Biometabolites, which offer a rich reservoir of candidate compounds for drug discovery in the battle against cancer. Recent research and development efforts concerning anti-cancer drugs derived from natural products have led to the identification of numerous candidate molecules that inhibit cancer cell proliferation and metastasis using a variety of mechanisms. Given its scope, the book offers a valuable resource for cancer biologists and general oncologists alike, while also benefitting research professionals in Science, Nursing, Medicine, Biochemistry, Genetics and Bioscience who wish to understand the fundamentals of prognosis and prediction in tumorigenesis. Moreover, the book provides an essential platform for understanding drug resistance mechanisms and combatting the growing menace of multidrug resistance.

Biostatistics is defined as much by its application as it is by theory. This book provides an introduction to biostatistical applications in modern cancer research that is both accessible and valuable to the cancer biostatistician or to the cancer researcher, learning biostatistics. The topical areas include active areas of the application of biostatistics to modern cancer research: survival analysis, screening, diagnostics, spatial analysis and the analysis of microarray data.
Biostatistics is an essential component of basic and clinical cancer research. The text, authored by distinguished figures in the field, addresses clinical issues in statistical analysis. The spectrum of topics discussed ranges from fundamental methodology to clinical and translational applications.

Brain metastases are the most dreaded complication of systemic cancer, affecting some 170,000 people a year, a far greater incidence than primary brain tumors. This book presents current information on the presentation and management of patients with brain metastases, providing available data, giving guidelines that can be applied in day to day practice, updated information for neurosurgeons, radiation oncologists, medical oncologists, and neuron-oncologists, and as an overview for physicians in training.

Breast cancer, being a disease with very high prevalence in the female population, has permanently attracted the attention of biologists, biochemists, pathologists, surgeons, and oncologists. In the U.S. alone approximately 120,000 new cases are diagnosed and 37,000 deaths a year are recorded as an outcome. Early diagnosis, clear cut prognosis and the hope of new therapeutic approaches has spurred the enthusiasm of researchers, who with the advent of newer methodologies, tried to employ it in different approaches to the breast cancer patient. In spite of the efforts devoted towards the creation of new approaches, reagents and procedures taking advantage of special characteristics of the breast tissue were slow to come. In general, most diagnostic and prognostic techniques were those shared and applied to other carcinomas. In the early seventies we discovered the first sets of antigens associated with breast epithelial tissue both in the mouse and the human. The recognition of such group of molecules, present in the milk fat globule membrane, gave impetus to several studies in these areas. These mammary cell surface antigens proved useful in several diagnostic approaches such as radioimaging, histochemical and serum assay procedures. However, the apparently inherent limitations of polyclonal antibodies reduced the impact of these novel approaches.